Combined Immunotherapy with Low-dose IL-2 Plus IFN- for Metastatic Renal Cell Carcinoma: Survival Benefit for Selected Patients with Lung Metastasis and Serum Sodium Level
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.